Prestige BioPharma Limited (950210.KS)
KRW 15050.0
(-4.57%)
KRW 15050.0
(-4.57%)
| Year | Eps | Eps Growth |
|---|---|---|
| 2023 | -547.81 KRW | -287.38% |
| 2022 | 292.35 KRW | 108.31% |
| 2021 | -3518.53 KRW | -2487.34% |
| 2020 | -135.99 KRW | -172.47% |
| 2019 | -49.91 KRW | -935.48% |
| 2018 | -4.82 KRW | 35.04% |
| 2017 | -7.42 KRW | 0.0% |
| Year | Eps | Eps Growth |
|---|---|---|
| 2023 Q2 | -216.79 KRW | -42.81% |
| 2023 Q3 | -24.09 KRW | 88.89% |
| 2023 Q4 | -154.51 KRW | -541.39% |
| 2023 Q1 | -151.80 KRW | -3.58% |
| 2022 Q1 | 891.00 KRW | 152.89% |
| 2022 Q4 | -146.55 KRW | 38.64% |
| 2022 FY | - KRW | 108.32% |
| 2022 Q2 | -304.15 KRW | -134.14% |
| 2022 Q3 | -238.84 KRW | 21.47% |
| 2021 Q1 | -169.24 KRW | -484.29% |
| 2021 Q4 | -1684.69 KRW | -18.04% |
| 2021 Q3 | -1427.20 KRW | -515.7% |
| 2021 Q2 | -231.80 KRW | -36.97% |
| 2021 FY | - KRW | -14202.97% |
| 2020 Q3 | -210.00 KRW | -8850.0% |
| 2020 Q1 | -9.60 KRW | 93.9% |
| 2020 FY | - KRW | 50.71% |
| 2020 Q2 | 2.40 KRW | 125.0% |
| 2020 Q4 | 44.04 KRW | 120.97% |
| 2019 FY | - KRW | -935.48% |
| 2019 Q3 | -8.82 KRW | 0.0% |
| 2019 Q4 | -157.27 KRW | -1683.11% |
| 2018 FY | - KRW | 35.04% |
| 2017 FY | - KRW | 0.0% |
| Name | Eps | Eps Difference |
|---|---|---|
| ORIENT BIO Inc. | 108.55 KRW | 604.661% |
| Green Cross Holdings Corporation | -1210.00 KRW | 54.726% |
| Green Cross Holdings Corporation | -2333.42 KRW | 76.523% |
| Pharmicell Co., Ltd. | 60.00 KRW | 1013.017% |
| Green Cross Corporation | -2333.42 KRW | 76.523% |
| GeneOne Life Science, Inc. | -1000.23 KRW | 45.232% |
| Celltrion, Inc. | 3759.00 KRW | 114.573% |
| Samsung Biologics Co.,Ltd. | 12.05 Thousand KRW | 104.546% |
| SK bioscience Co.,Ltd. | 291.00 KRW | 288.251% |
| SK Biopharmaceuticals Co., Ltd. | -419.89 KRW | -30.465% |